Plavix does not affect overall risk of death in patients with heart disease.
Long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease.
Pharmaceuticals, Biotechnology and Life Sciences
Long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease.
Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents.
Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.
Inaffit is voluntarily recalling all lots of Natureal light green and dark green capsules to the consumer level after FDA laboratory testing found Natureal to contain sibutramine.
Zenobia Company LLC. of Yonkers, NY is recalling Ground Flax Seed Meal, because they have the potential to be contaminated with Salmonella.
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…
Sanofi and Regeneron Inc. have announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against…
Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…